stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Price to free cash flow
As of 5 November 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a price to free cash flow of 12.2×. Over the past ten years it has ranged from 0.0× (September 2024) to 55.1× (May 2017); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 24.8× and below the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 15.8× | (45.66%) |
| FY2024 | 29.1× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 6.1× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 12.2× | (3.16%) |
| Jun 2026 | 12.6× | 7.11% |
| Mar 2026 | 11.8× | (25.62%) |
| Dec 2025 | 15.8× | 30.26% |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc | 12.2× |
| ADMA ADMA Biologics Inc compare | 24.5× |
| VCEL Vericel Corporation compare | 45.4× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement